Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma.
Mariona RiudavetsJoaquim Bosch-BarreraLuís Cabezón-GutiérrezPilar Diz TaínAinhoa HernándezMiriam AlonsoRemei BlancoElisa GálvezAmelia InsaXabier MielgoTeresa MoránSantiago PonceDiana RoaJosé Miguel SánchezMargarita Majem TarruellaPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2021)
Our data indicate that the combination of docetaxel and nintedanib can be considered to be an effective treatment for EGFR TKI-resistant EGFR-mutant NSCLC.
Keyphrases
- epidermal growth factor receptor
- advanced non small cell lung cancer
- tyrosine kinase
- idiopathic pulmonary fibrosis
- small cell lung cancer
- interstitial lung disease
- wild type
- locally advanced
- electronic health record
- systemic sclerosis
- big data
- rheumatoid arthritis
- radiation therapy
- machine learning
- squamous cell carcinoma
- smoking cessation
- replacement therapy
- chronic myeloid leukemia